Geode Capital Management
BCLI

Geode Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Geode Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54,582
Closed -$61.1K – 4485
2025
Q2 		$61.1K Sell
54,582
-3,583
-6% -$4.01K ﹤0.01% 4176
2025
Q1 		$73.3K Buy
58,165
+5,664
+11% +$10K ﹤0.01% 4109
2024
Q4 		$119K Buy
52,501
+6,980
+15% +$12.9K ﹤0.01% 4056
2024
Q3 		$152K Buy
45,521
+13,235
+41% +$62.5K ﹤0.01% 3985
2024
Q2 		$164K Buy
32,286
+8,483
+36% +$63.6K ﹤0.01% 3985
2024
Q1 		$202K Hold
23,803
– – ﹤0.01% 3941
2023
Q4 		$97.5K Buy
23,803
+3,085
+15% +$9.25K ﹤0.01% 4192
2023
Q3 		$62.2K Buy
20,718
+2,338
+13% +$53.2K ﹤0.01% 4370
2023
Q2 		$568K Hold
18,380
– – ﹤0.01% 3592
2023
Q1 		$910K Buy
18,380
+133
+0.7% +$3.86K ﹤0.01% 3392
2022
Q4 		$448K Sell
18,247
-195
-1% -$7.29K ﹤0.01% 3704
2022
Q3 		$1.22M Buy
18,442
+48
+0.3% +$2.41K ﹤0.01% 3287
2022
Q2 		$761K Sell
18,394
-505
-3% -$22.7K ﹤0.01% 3539
2022
Q1 		$952K Buy
18,899
+359
+2% +$17.6K ﹤0.01% 3642
2021
Q4 		$1.11M Buy
18,540
+157
+0.9% +$7.73K ﹤0.01% 3667
2021
Q3 		$909K Buy
18,383
+707
+4% +$37.2K ﹤0.01% 3731
2021
Q2 		$1.01M Sell
17,676
-14,208
-45% -$759K ﹤0.01% 3599
2021
Q1 		$1.83M Buy
31,884
+4,822
+18% +$364K ﹤0.01% 3291
2020
Q4 		$1.84M Buy
27,062
+402
+2% +$54.7K ﹤0.01% 3128
2020
Q3 		$6.77M Buy
26,660
+425
+2% +$87K ﹤0.01% 2213
2020
Q2 		$4.41M Buy
26,235
+14,929
+132% +$1.61M ﹤0.01% 2406
2020
Q1 		$786K Buy
11,306
+1,757
+18% +$137K ﹤0.01% 3108
2019
Q4 		$613K Hold
9,549
– – ﹤0.01% 3437
2019
Q3 		$558K Buy
9,549
+745
+8% +$43.9K ﹤0.01% 3436
2019
Q2 		$521K Buy
8,804
+1,786
+25% +$104K ﹤0.01% 3450
2019
Q1 		$456K Hold
7,018
– – ﹤0.01% 3468
2018
Q4 		$373K Hold
7,018
– – ﹤0.01% 3475
2018
Q3 		$402K Hold
7,018
– – ﹤0.01% 3545
2018
Q2 		$410K Buy
7,018
+1,304
+23% +$76.7K ﹤0.01% 3504
2018
Q1 		$269K Hold
5,714
– – ﹤0.01% 3600
2017
Q4 		$335K Hold
5,714
– – ﹤0.01% 3499
2017
Q3 		$353K Hold
5,714
– – ﹤0.01% 3473
2017
Q2 		$356K Buy
5,714
+823
+17% +$50.7K ﹤0.01% 3489
2017
Q1 		$311K Buy
4,891
+806
+20% +$41.9K ﹤0.01% 3494
2016
Q4 		$155K Hold
4,085
– – ﹤0.01% 3693
2016
Q3 		$146K Hold
4,085
– – ﹤0.01% 3697
2016
Q2 		$147K Hold
4,085
– – ﹤0.01% 3687
2016
Q1 		$163 Hold
4,085
– – ﹤0.01% 3694
2015
Q4 		$175K Hold
4,085
– – ﹤0.01% 3727
2015
Q3 		$140K Hold
4,085
– – ﹤0.01% 3802
2015
Q2 		$221K Hold
4,085
– – ﹤0.01% 3546
2015
Q1 		$272K Buy
4,085
+2,936
+256% +$186K ﹤0.01% 3463
2014
Q4 		$82K Buy
+1,149
New +$60.4K ﹤0.01% 3817

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Geode Capital Management's BCLI Position: Q3 2025 in Review

Geode Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 54,582 shares — an estimated $61.1K sold.

Geode Capital Management first reported a position in BCLI in Q4 2014 and held it in 43 quarters. The position peaked at $6.77M in Q3 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Geode Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Geode Capital Management sold 54,582 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $61.1K.
  • Geode Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 43 quarters.
  • Geode Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $6.77M in Q3 2020.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Geode Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.